Symptom severity and the generalizability of antidepressant efficacy trials: Changes during the past 20 years

Journal of Clinical Psychopharmacology

Volumn 36, Issue 2, 2016, Pages 153-156

  Zimmerman, Mark ^a   Clark, Heather L ^a   Multach, Matthew D ^a   Walsh, Emily ^a   Rosenstein, Lia K ^a   Gazarian, Douglas ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

antidepressant efficacy trials; generalizability; Hamilton Rating Scale for Depression; inclusion criteria; major depressive disorder; symptom severity

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER, MAJOR; PROCEDURES; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84957653087     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000466     Document Type: Article

References (28)

1. Zimmerman M, Mattia JI, Posternak MA,. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice. Am J Psychiatry. 2002; 159: 469-473.
2. Van der Lem R, Van der Wee NJ, Van Veen T, The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. Psychol Med. 2011; 41: 1353-1363.
3. Wisniewski S, Rush A, Nierenberg A, Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR∗D report. Am J Psychiatry. 2009; 166: 599-607.
4. Zetin M, Hoepner CT,. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol. 2007; 27: 295-301.
5. Zimmerman M, Chelminski I, Posternak M,. Exclusion criteria used in antidepressant efficacy trials: Consistency across studies and representativeness of samples included. J Nerv Ment Dis. 2004; 192: 87-94.
6. Hamilton M,. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62.
7. Zimmerman M, Clark HL, Multach MD, Have treatment studies of depression become even less generalizable? A review of the inclusion and exclusion criteria used in placebo-controlled antidepressant efficacy trials published during the past 20 years. Mayo Clin Proc. 2015; 90: 1180-1186.
8. Fournier JC, DeRubeis RJ, Hollon SD, Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010; 303: 47-53.
9. Khan A, Leventhal RM, Khan SR, Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002; 22: 40-45.
10. Kocsis JH, Croughan JL, Katz MM, Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry. 1990; 147: 621-624.
11. Papakostas G, Fava M,. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009; 19: 34-40.
12. Undurraga J, Baldessarini R,. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacol. 2012; 37: 851-864.
13. Montgomery SA, Asberg M,. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382-389.
14. Zimmerman M, Posternak MA, Chelminski I,. Symptom severity and exclusion from antidepressant efficacy trials. J Clin Psychopharmacol. 2002; 22: 610-614.
15. Kahn A, Warner H, Brown W,. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000; 57: 311-317.
16. Gelenberg A, Thase M, Meyer R, The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008; 69: 1513-1528.
17. Lee S, Walker JR, Jakul L, Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety. 2004; 19: 10-19.
18. Fava M, Evins AE, Dorer DJ, The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003; 72: 115-127.
19. Kirsch I, Deacon BJ, Huedo-Medina TB, Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008; 5: e45.
20. Rush AJ, First MB, Blacker D,. Handbook of Psychiatric Measures. 2nd ed. Washington: American Psychiatric Publishing, Inc; 2008.
21. Zimmerman M, Martinez JH, Young D, Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013; 150: 384-388.
22. Gilbody SM, House AO, Sheldon TA,. Psychiatrists in the UK do not use outcomes measures. National survey. Br J Psychiatry. 2002; 180: 101-103.
23. Zimmerman M, McGlinchey JB,. Why don't psychiatrists use scales to measure outcome when treating depressed patients? J Clin Psychiatry. 2008; 69: 1916-1919.
24. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Washington, DC: American Psychiatric Association; 2010.
25. US Food and Drug Administration Code of Federal Regulations Title 21. In: Department of Health and Human Services., ed. 21CFR20157: US Food and Drug Administration. Washington, DC; 2014.
26. Turner EH, Matthews AM, Linardatos E, Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358: 252-260.
27. Koesters M, Guaiana G, Cipriani A, Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry. 2013; 203: 179-187.
28. Taylor D, Sparshatt A, Varma S, Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014; 348: g1888.